What drugs will be assessed by the Transparency Council at the next meeting?

The Council will meet on January 10 (Monday). The agenda is:
Preparation of a position on the evaluation of the drug Jardiance (empagliflozinum) in the indication: chronic heart failure in adult patients with reduced left ventricular ejection fraction (LVEF ≤ 40%) and persistent disease symptoms in NYHA class II-IV.
Discussion on the content of documents prepared by the Council.
Preparation of an opinion on the draft health policy program of a local government unit: "Program for the prevention and early detection of overweight and obesity among students attending primary schools in the Dywity Commune".

Preparation of an opinion on the reimbursement of drugs containing active substances:
• azathioprinum in the indication: autoimmune diseases other than those specified in the SPC,
• cyclophosphamidum in the indications: autoimmune diseases; amyloidosis,
• colecalciferolum in the indication: steroid osteoporosis - prophylaxis,
• risedronatum natricum in the indication: steroid osteoporosis - prophylaxis.

Source: AOTMiT